The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 652-657

  Rodriguez J ^a   Conde, E ^b   Gutierrez A ^a   Arranz, R ^c   Leon A ^d   Marin J ^e   Bendandi, M ^f   Albo, C ^g   Calballero, M D ^h  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL DE JEREZ   (Spain)

^e Hospital Nuestra Senora de Aranzazu   (Spain)

^f Clinica Universidadde Navarra   (Spain)

^g HOSPITAL XERAL CÍES   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Autologous stem cell transplantation; Complete response; Consolidation; Front line; Peripheral T cell lymphoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SPAIN; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; WHOLE BODY RADIATION;

EID: 34047159303     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl466     Document Type: Article

References (28)

1. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514-4520.
2. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76-82.
3. Armitage JO, Vose JM, Linder J et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1783-1790.
4. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45-50.
5. Vose J. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 2005; 106: 811.
6. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
7. Kewalramani T, Nimer S, Zelenetz A et al. Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT). Blood 2002; 100: 646a.
8. Caballero MD, Perez-Simon JA, Iriondo A et al. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GELTAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140-151.
9. Blystad AK, Enblad G, Kvaloy S et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711-716.
10. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
11. Rodriguez J, Cabanillas F, McLaughlin P et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992; 3: 711-717.
12. Rodriguez J, Caballero D, Gutierrez A et al. Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL): The Spanish Lymphoma Cooperative Group (GEL-TAMO) experience. Ann Oncol 2005; 16: V56.
13. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
16. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
17. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
18. Mounier N, Gisselbrecht C, Briere J et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004; 22: 2826-2834.
19. Reimer P, Ruediger T, Schertlin T et al. Autologous stem cell transplantation as first-line therapy in peripheral T-cell lymphomas. A prospective multicenter study. Blood 2005; 106: 2074.
20. Lopez-Guillermo A, Mercadal S, Briones J et al. Intensive chemotherapy (highdose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation (ASCT) in previously untreated patients with peripheral T-cell lymphoma (PTCL). Results of a prospective phase II study from the GELCAB. Blood 2005; 106: 2077.
21. Cortelazzo S, Tarella C, Dodero A et al. Long-term follow-up of high-dose chemotherapy followed by autologous stem cell transplantation in peripheral T-cell lymphomas at diagnosis. Blood 2004; 104: 909.
22. D'Amore F. High-dose therapy and autologous stem cell transplant as first line treatment in peripheral T-cell lymphomas. Ann Oncol 2005; 16: v15-v26.
23. Tilly H, Gaulard P, Lepage E et al. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 1997; 90: 3727-3734.
24. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-2706.
25. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: Differential diagnostic and prognostic aspects - a review. J Pathol 2003; 200: 4-15.
26. Thompson MA, Pro B, Sarris A et al. Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-Cell or peripheral T-cell lymphoma. Blood 2005; 106: 2681.
27. Piekarz RL, Robey RW, Zhan Z et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103: 4636-4643.
28. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.